LAVAL, Quebec, May 27, 2020 /CNW/ -- Bausch + Lomb, a
leading global eye health business of Bausch Health Companies
Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the
European launch of the company's first Extended Depth of Focus
intraocular lens (IOL), LuxSmart™, and a new monofocal IOL,
LuxGood™. Both feature preloaded delivery systems and Pure
Refractive Optics (PRO) Technology.
The LuxSmart and LuxGood IOLs utilize PRO technology, a design
that is based only on refractive profiles and has no diffraction
areas so patients are less likely to experience
dysphotopsia.1,2 With the launch of this new platform,
Bausch + Lomb now offers a complete range of innovative IOLs in
Europe. Additionally, a toric
version will become available later this year.
"LuxSmart and LuxGood feature an innovative premium optic design
and PRO technology that reduces dysphotopsia, a common phenomenon
that can occur in some premium IOLs and compromise a patient's
vision," said Thomas Appio,
president, Bausch + Lomb/International. "Bausch + Lomb will
continue to focus its efforts on developing innovative products
that meet the growing patient demand for premium cataract
options."
LuxSmart and LuxGood also feature a proprietary acrylic
hydrophobic cross-linked copolymer material with an ultraviolet
(UV) absorber that protects the eyes against damaging UV light. The
platform is based on a 4-point fixation haptic design to achieve
lens centration, rotational stability, posterior capsule
opacification resistance3,4,5 and greater refractive
predictability.6 The platform is available with and
without violet light filtering.
Currently, more than 1.7 billion people in the world are
afflicted with presbyopia, which typically begins around 40 to 45
years of age.7
About Bausch + Lomb
Bausch + Lomb, a leading global
eye health business of Bausch Health Companies Inc., is solely
focused on helping people see. Its core businesses include
over-the-counter products, dietary supplements, eye care products,
ophthalmic pharmaceuticals, contact lenses, lens care products,
ophthalmic surgical devices and instruments. Bausch + Lomb
develops, manufactures and markets one of the most comprehensive
product portfolios in the industry, which is available in more than
100 countries. For more information,
visit www.bauschsurgical.eu.
About Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve
people's lives with our health care products. We develop,
manufacture and market a range of pharmaceutical, medical device
and over-the-counter products, primarily in the therapeutic areas
of eye health, gastroenterology and dermatology. We are delivering
on our commitments as we build an innovative company dedicated to
advancing global health. More information can be found at
www.bauschhealth.com.
Forward-looking Statements
This news release may
contain forward-looking statements, which may generally be
identified by the use of the words
"anticipates," "expects," "intends," "plans," "should," "could," "would," "may,"
"believes," "estimates," "potential," "target," or "continue" and
variations or similar expressions. These statements are based upon
the current expectations and beliefs of management and are subject
to certain risks and uncertainties that could cause actual results
to differ materially from those described in the forward-looking
statements. These risks and uncertainties include, but are not
limited to, the risks and uncertainties discussed in the Company's
most recent annual report on Form 10-K and detailed from time to
time in Bausch Health's other filings with the U.S. Securities and
Exchange Commission and the Canadian Securities Administrators,
which factors are incorporated herein by reference. They also
include, but are not limited to, risks and uncertainties caused by
or relating to the evolving COVID-19 pandemic, and the fear of that
pandemic and its potential effects, the severity, duration and
future impact of which are highly uncertain and cannot be
predicted, and which may have a material adverse impact on the
Company, including but not limited to its project development
timelines, and costs (which may increase). Readers are cautioned
not to place undue reliance on any of these forward-looking
statements. These forward-looking statements speak only as of the
date hereof. Bausch Health undertakes no obligation to update any
of these forward-looking statements to reflect events or
circumstances after the date of this news release or to reflect
actual outcomes, unless required by law.
References:
1. Breyer, D, Kaymak, H et al. Multifocal Intraocular Lenses and
Extended Depth of Focus Intraocular Lenses. Asia-Pac J Ophthalmol
2017; 6:339-349.
2. Lee, Y, Grzegorz L et al. Assessment of the image quality of
extended depth-of-focus intraocular lens models in polychromatic
light. J Cataract Refract Surg 2020; 46: 108-115.
3. Prinz A, Neumayer T, Buehl W et al. Rotational stability and
posterior capsule opacification of a plate-haptic and an
open-loop-haptic intraocular lens. J Cataract Refract Surg 2011;
37:251–257.
4. Hirnschall N, Nishi Y, Crnej A, et al. Capsular bag stability
and posterior capsule opacification of a plate-haptic design
microincision cataract surgery intraocular lens: 3-year results of
a randomised trial. Br J Ophthalmol 2013;97: 1565–1568.
5. Choi M, Lazo MZ, Kang M et al. Effect of number and position of
intraocular lens haptics on anterior capsule contraction: a
randomized, prospective trial. BMC Ophthalmology (2018) 18:78.
6. Alió JL, Plaza-Puche AB, Javaloy J et al. Clinical and Optical
Intraocular Performance of Rotationally Asymmetric Multifocal IOL
Plate-Haptic Design Versus C-Loop Haptic Design. Journal of
Refractive Surgery. 2013;29(4):252-259
7. Fundamentals of Presbyopia: visual processing and binocularity
in its transformation. Olga I.
Rozanova, Andrey G. Shchuko and Tatyana S. Mischenko (2018).
®/TM are trademarks of Bausch & Lomb Incorporated or its
affiliates.
Any other product/brand names are trademarks of the respective
owners.
© 2020 Bausch & Lomb Incorporated or its affiliates.
Investor
Contact:
|
Media
Contact:
|
Arthur
Shannon
|
Lainie
Keller
|
arthur.shannon@bauschhealth.com
|
lainie.keller@bauschhealth.com
|
(514)
856-3855
|
(908)
927-1198
|
(877) 281-6642 (toll
free)
|
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bausch--lomb-announces-the-european-launch-of-luxsmart-and-luxgood-preloaded-intraocular-lenses-301065680.html
SOURCE Bausch Health Companies Inc.